Oxford PharmaScience Advances Partnership Discussions for Oxprofen Platform
September 2025

Oxford PharmaScience is advancing development of its Oxprofen™ fast-acting ibuprofen platform, following successful confirmation of API manufacturing economics at commercial scale and the development of a fully taste-masked, fast-acting orally dispersible tablet (ODT) format.

In parallel, the company is progressing new intellectual property filings covering next-generation formulations designed to further enhance the speed and sensory profile of fast-acting oral analgesics.

Oxford PharmaScience is in active discussions with leading pharmaceutical partners to develop and commercialize the Oxprofen platform across prescription and over-the-counter pain-relief markets.

Regulatory pathways for the LDH-based formulation remain well established, enabling streamlined registration via 505(b)(2) and hybrid procedures — as well as direct OTC routes where appropriate.

The company is also pursuing new consumer-health opportunities through its Ellactiva® soft-chew supplement line, which continues to expand in international markets.